Format

Send to

Choose Destination
Methods Mol Biol. 2016;1428:163-75. doi: 10.1007/978-1-4939-3625-0_11.

FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines.

Author information

1
TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University, TRON gGmbH, Freiligrathstrasse 12, 55131, Mainz, Germany.
2
TRON-Translational Oncology at the University Medical Center of Johannes Gutenberg University, TRON gGmbH, Freiligrathstrasse 12, 55131, Mainz, Germany. ugur.sahin@tron-mainz.de.

Abstract

Intranodal immunization with antigen-encoding naked mRNA has proven to be an efficacious and safe approach to induce antitumor immunity. Thanks to its unique characteristics, mRNA can act not only as a source for antigen but also as an adjuvant for activation of the immune system. The search for additional adjuvants that can be combined with mRNA to further improve the potency of the immunization revealed Fms-like tyrosine kinase 3 (FLT3) ligand as a potent candidate. Systemic administration of the dendritic cell-activating FLT3 ligand prior to or along with mRNA immunization-enhanced priming and expansion of antigen-specific CD8(+) T cells in lymphoid organs, T-cell homing into melanoma tumors, and therapeutic activity of the intranodally administered mRNA. Both compounds demonstrate a successful combination in terms of boosting the immune response. This chapter describes methods for intranodal immunization with naked mRNA by co-administration of FLT3 ligand, which leads to strong synergistic effects.

KEYWORDS:

Cancer vaccination; Dendritic cell; FLT3 ligand; IVT-RNA; Immunotherapy; Intranodal injection; RNA vaccine; Vaccine adjuvants

PMID:
27236799
DOI:
10.1007/978-1-4939-3625-0_11
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center